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Creatine supplementation does not decrease total plasma
homocysteine in chronic hemodialysis patients.
Background. Hyperhomocysteinemia is present in the major-
ity of chronic hemodialysis patients. Treatment with folic acid,
vitamin B12, and vitamin B6 cannot fully normalize plasma ho-
mocysteine concentrations (tHcy). Previously we have demon-
strated the tHcy-lowering effect of creatine supplementation in
an animal model of uremia (Kidney Int 64:1331–1337, 2003).
The present study investigates the effects of creatine supple-
mentation on tHcy in a vitamin-repleted chronic hemodialysis
population.
Methods. Forty-five hemodialysis patients receiving folic acid
and vitamin B6 and B12 were included. Patients were treated
with creatine (2 g/day) or placebo during 2 treatment periods of
4 weeks, separated by a washout of 4 weeks. Plasma tHcy, crea-
tine, Kt/Vurea, folic acid, vitamin B12, and routine biochemistry
were determined, as well as the prognostic inflammatory and
nutritional index.
Results. All patients had elevated tHcy concentrations (21.2±
5.6 lmol/L). Creatine treatment resulted in increased plasma
and red blood cell creatine levels, documenting uptake of crea-
tine. Creatine did not affect tHcy concentrations. There was no
relationship between plasma creatine concentrations and tHcy
concentrations. No changes in body weight, routine biochem-
istry, nutritional status, folic acid, or vitamin B12 were observed
during the study.
Conclusion. Creatine supplementation at a rate of 2 g/day
does not further decrease tHcy concentrations in chronic dial-
ysis patients already treated with high dose folic acid, vitamin
B6, and B12 supplementation.
Hyperhomocysteinemia, a raised plasma concentra-
tion of the sulfur amino acid homocysteine, is observed
in several genetic and acquired disorders. The majority
of patients with end-stage renal disease (ESRD) have
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a moderate degree of hyperhomocysteinemia [1]. Treat-
ment of hyperhomocysteinemia consists of folic acid and
vitamin B6, B12 supplements. Folic acid supplementation
can reduce plasma tHcy about 30% in uremic patients,
whereas the effect of vitamin B6 and B12 is in general
much less pronounced [2, 3]. However, the majority of
ESRD patients maintain elevated plasma tHcy concen-
trations when treated with high dose multivitamin supple-
mentation. Betaine can further decrease post-methionine
loading tHcy concentrations by 18%, in addition to folic
acid supplementation [4]. Additional tHcy-lowering ther-
apies are necessary in these patients in order to attain
normal tHcy concentrations.
Creatine synthesis and homocysteine (Hcy)-formation
are metabolically connected (Fig. 1). Hcy [1, 5] is de-
rived from methionine in a multiple step metabolic
cycle (Fig. 1). Methionine can intracellularly be con-
verted to S-adenosyl methionine, a sulfonium compound
with a highly reactive methyl group, which acts as a
universal methyl donor in numerous transmethylation
reactions in vivo. The demethylated product S-adenosyl-
homocysteine, a thioether, is readily hydrolyzed to Hcy
and adenosine by S-adenosyl-homocysteine hydrolase.
Transsulfuration of homocysteine to yield cystathion-
ine is favored in conditions with methionine excess.
Remethylation of homocysteine to methionine occurs
in conditions of low methionine intake through methyl-
donation from 5-methyltetrahydrofolate (5-CH3THF)
by means of methionine synthase. Creatine is synthe-
sized in humans by two successive metabolic steps
(Fig. 1). Guanidinoacetate is synthesized from glycine
and arginine by arginine: glycine aminidinotransferase
(AGAT; EC 2.1.4.1), mainly in the kidney. Second,
guanidinoacetate is methylated in the liver to creatine
by guanidinoacetate-methyltransferase (GAMT) (EC
2.1.1.2) with S-adenosylmethionine as methyl-donor [6,
7]. Dietary intake and endogenous synthesis in liver com-
pensate for a daily loss as creatinine of about 2%. Crea-
tine supplementation represses AGAT biosynthesis and,
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Fig. 1. Overview of homocysteine and cre-
atine metabolism. THF: tetrahydrofolate;
5CH3-THF: 5-methyltetrahydrofolate; 5,10-
CH2-THF: 5,10 methylene tetrahydrofolate;
Ser: serine; Gly: glycine; SAM: S-adenosyl
methionine; SAH: S-adenosyl homocysteine;
Hcy: homocysteine; Met: methionine. En-
zymes are (1) arginine:glycine amidinotrans-
ferase (AGAT); (2) methionine adenosyl-
transferase; (3) guanidinoacetate methyl-
transferase (GAMT); (4) S-adenosyl homo-
cysteine hydrolase; (5) methionine synthase;
(6) 5,10-CH2-THF reductase; (7) serine-
hydroxy methyltransferase; (8) cystathionine-
b–synthase.
consequently, guanidinoacetate and creatine formation
(Fig. 1). Methylation of guanidinoacetate during crea-
tine biosynthesis has been estimated to account for up
to 70% of the transmethylation reactions in the body
with formation of Hcy [8, 9]. Exogenous creatine sup-
plementation can, thus, be expected to decrease endoge-
nous Hcy synthesis. Inhibition of the methyltransferase
reactions has been described in uremia due to a reduced
S-adenosylmethionine (SAM)/S-adenosylhomocysteine
(SAH) ratio, and protein hypomethylation and reduced
protein repair are observed in uremic subjects [10,
11]. The influence of creatine on tHcy concentrations,
SAM/SAH ratios, and the methyltransferase reactions in
humans is currently unknown. Creatine supplementation
could reduce the guanidinoacetate-methyltransferase
reaction and consequent Hcy-formation. In an ani-
mal model of chronic renal failure we have recently
demonstrated a pronounced beneficial effect of creatine
supplementation on plasma tHcy concentrations. tHcy
concentrations were lowered by 22% in creatine-treated
animals compared to control diet–fed uremic animals
[12]. Whether creatine can lower tHcy in humans as ob-
served in our animal model is currently unknown.
The present study investigates the effect of crea-
tine supplementation on plasma tHcy concentrations in
chronic hemodialysis patients already treated with high-
dose multivitamin supplementation.
METHODS
Study design and population
Forty-nine hemodialysis patients were recruited. Dial-
ysis was performed with a low-flux triacetate dialyzer
(Sureflux-L; Nipro, Osaka, Japan) for 4 to 5 hours 3 times
weekly for at least 3 months. Exclusion criteria were:
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Fig. 2. Treatment schedule.
due to cognitive, social, or psychiatric problems, and in-
ability to provide informed consent. All patients were
treated with folic acid 5 mg, pyridoxine 50 mg, and vita-
min B12 12 lg orally 3 times a week for at least 3 months.
Written informed consent was obtained from all partic-
ipants. The study protocol was approved by the Ethical
Committee of AZ Sint-Jan AV. Sample size estimation
(type I error = 0.05; type II error = 0.20), based on the
Hcy lowering in our animal study ( tHcy = 20%) and
tHcy concentrations in dialysis patients, revealed suffi-
cient statistical power of the present study.
The study followed a double-blind, placebo-controlled,
crossover design (Fig. 2). Patients received 2 g creatine or
placebo daily in the evening during 2 treatment periods
of 4 weeks, in random order, and separated by a washout
period of 4 weeks. Creatine monohydrate (CreaPure)
was obtained from Degussa Bioactives (Freising,
Germany). Placebo tablets contained Fast Flo lactose
(Foremost Farms, Baraboo, WI, USA). An exact num-
ber of tablets was supplied, and pills were counted to
ascertain compliance. Treatment duration, blood flow,
dialysate flow, and membrane surface area were deter-
mined by the attending nephrologists, but no changes
were made during the study period. Single pool Kt/Vurea
was calculated at the start and end of the study, where K =
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dialyzer urea clearance, T = duration of dialysis, and
V = urea distribution volume at the end of dialysis.
Predialysis blood samples were obtained at baseline
and after 4 weeks in both treatment periods. EDTA-
samples for tHcy determinations were transported on
ice, centrifuged immediately, and stored at −20◦C until
testing.
Biochemical determinations
Plasma creatinine concentrations were determined us-
ing a compensated rate-blanked Jaffe´ based method
(Roche Diagnostics, Mannheim, Germany) on a Mod-
ular P analyzer (Roche Diagnostics) according to
the manufacturer’s procedure. Plasma urea concentra-
tions and aspartate-aminotransferase (AST), alanine-
aminotransferase (ALT), alkaline phosphatase, creatine
kinase, and c-glutamyl transferase (GGT) activities were
determined on a Modular P analyzer using commercial
reagents (Roche Diagnostics).
Total plasma homocysteine concentrations were deter-
mined using a fluorescence polarization immunoassay on
an Axsym analyzer (Abbott Laboratories, Abbott Park,
IL, USA).
Plasma folate and vitamin B12 concentrations were
determined using an electrochemiluminescence assay
(Roche Diagnostics) on an Elecsys 2010 analyzer (Roche
Diagnostics). Plasma and erythrocyte creatine concen-
trations were determined enzymatically as described
before [13]. Plasma creatine was determined without de-
proteinization, whereas erythrocyte creatine was deter-
mined after deproteinization with 5-sulfosalicylic acid.
No analytical interference of creatine on tHcy was ob-
served. The prognostic inflammatory and nutritional
index (PINI) was calculated as PINI = [(a1-acid glyco-
protein (mg/L) × CRP (mg/L)]/[(albumin (g/L) × preal-
bumin (mg/L)] [14, 15]. a1-acid glycoprotein, albumin,
and prealbumin were determined nephelometrically
using commercial reagents (Dade Behring, Marburg,
Germany) on a BN II nephelometer. CRP was deter-
mined turbidimetrically on a Modular P analyzer (Roche
Diagnostics).
Statistics
Data are expressed as mean ± SD, unless parame-
ters were not normally distributed [median (interquartile
range)]. Student t test was used to compare sepa-
rate groups when appropriate; otherwise nonparametric
group comparison was performed using Mann-Whitney
U test. Associations between continuous variables were
examined using Spearman rank correlation analysis. In
order to estimate the effect of creatine treatment on the
tHcy concentrations in this crossover framework, a mixed
effect model was fitted treating patient as a random effect
while the treatment mode, period, and carry-over were




Age years 69 ± 12 71 ± 8
Body mass index kg/m2 24 ± 4 25 ± 3
Plasma creatinine lmol/L 751 ± 203 698 ± 221
Plasma urea mmol/L 22.3 ± 5.7 22.5 ± 6.5
Kt/Vurea 1.4 ± 0.4 1.3 ± 0.2
modeled as fixed effects [16]. Model fitting was performed
using SAS software (PROC MIXED) (release 8.1, SAS
Institute, Inc., Cary, NC, USA). Differences were consid-
ered significant at P less than 0.05.
RESULTS
Baseline patient characteristics
Forty-five hemodialysis patients (24 males, 21 females)
with a mean age of 70 ± 10 years (range 35–88) were
included in this study. Four patients were excluded from
the study (2 patients were transplanted during the study,
1 died, and 1 quit the study). Twenty-five patients re-
ceived creatine, and 20 patients received placebo in the
first treatment period. No baseline differences in age,
gender distribution, body mass index, tHcy concentra-
tions, or dialysis parameters were observed between
placebo and creatine groups for both treatment periods
(Table 1).
Plasma tHCY and creatine concentrations
No significant changes in plasma tHcy concentrations
were observed during treatment with creatine or placebo.
Pre- and post-treatment tHcy concentrations were com-
parable in both creatine or placebo groups during the 2
treatment periods (Fig. 3). Plasma and red cell creatine
concentrations were significantly elevated in the creatine
treated groups, whereas comparable concentrations were
observed before and after placebo treatment, document-
ing the uptake of creatine (Fig. 3 and Table 3).
No difference in baseline creatine concentrations was
observed between the first and second treatment period,
documenting the washout effect (Fig. 3). Male patients
had significantly higher tHcy concentrations (23.3 ±
3.7 lmol/L) compared to female patients (18.7 ±
6.1 lmol/L; P = 0.005). No effect of creatine supple-
mentation on tHcy concentrations was observed in either
male or female patients (data not shown).
The results of the mixed effects model fit for tHcy are
shown in Table 2. No treatment, period, or carryover ef-
fects were detected. No correlation between plasma cre-
atine and tHcy concentrations was observed (r = −0.08;
P = 0.76).
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Fig. 3. Plasma homocysteine (tHcy) and creatine concentrations in
both treatment periods. Black bars represent concentrations before
treatment, whereas gray bars represent concentrations after treatment.
Creatine concentrations were significantly higher in the creatine groups
compared to the placebo groups (∗P < 0.0001). No difference in tHcy
concentrations was observed.
Table 2. Results of the mixed effects model fit for tHcy
b (SE) t value Significance
Treatment (creatine vs. placebo) −0.253 (0.634) −0.40 P = 0.69
Carryover effect −0.259 (1.409) −0.18 P = 0.86
Period (2nd vs. 1st) −0.393 (0.634) −0.62 P = 0.54
Plasma folate and vitamin B12 concentrations
All patients had elevated plasma concentrations of fo-
late and vitamin B12 (Table 3). No difference in plasma
folate or vitamin B12 was observed between creatine- or
placebo-treated groups. No significant relationship be-
tween tHcy and plasma folate or vitamin B12 concentra-
tions was observed.
Nutritional status and dialysis
Nutritional status remained constant during the study
period. No difference over time in total protein, albu-
min, prealbumin concentrations, and PINI scores were
observed in any of the groups. A significant relationship
between total protein concentration and tHcy was ob-
served (r = 0.20; P = 0.006). No relationship between
albumin (r = 0.103; P = 0.17), prealbumin (r = 0.10; P =
0.20) concentrations, or PINI scores (r = 0.01; P = 0.87)
and tHcy was observed in this population. Body weight
and Kt/Vurea remained constant during the study period.
No difference in Kt/Vurea between creatine- and placebo-
treated groups [1.3 ± 0.3 vs. 1.4 ± 0.3 (post-treatment)]
was observed. Baseline tHcy concentrations correlated
with Kt/Vurea (r = −0.35; P = 0.01) and plasma creatinine
concentrations (r = 0.40; P = 0.004) (Fig. 4). No relation-
ship after treatment was observed between Kt/Vurea and
tHcy concentrations.
DISCUSSION
Hcy metabolism is tightly regulated under normal con-
ditions. However, in situations with compromised Hcy
homeostasis such as dialysis, creatine supplementation
could have a more prominent tHcy-lowering effect [17].
In our dialysis patients treated with folic acid, vitamin
B6, and B12, plasma tHcy concentrations remained mod-
erately elevated, an observation in agreement with the
well-known resistance to therapy in uremia. In contrast to
the effects in experimental animals [12, 18], oral creatine
supplementation at a rate of 2 g/day did not lower plasma
tHcy concentrations in our dialysis population. tHcy con-
centrations were comparable after treatment with cre-
atine and placebo. This observation is in line with the
absence of an effect of creatine supplementation on tHcy
in young healthy volunteers [19].
Plasma creatine and creatinine concentrations were
higher in creatine-supplemented subjects, documenting
uptake and metabolization of creatine. The absence of
effect could, thus, not be attributed to a limited uptake of
creatine. In addition, the sample size was sufficiently large
to demonstrate a decrease in plasma tHcy as observed
previously in our animal study [12]. The dose of 2g cre-
atine daily was chosen on the basis of existing treatment
schedules. In healthy subjects, creatine at a maintenance
dose of 2 g is used as a performance enhancing nutritional
supplement, with documented uptake of creatine in the
skeletal muscle [20]. Loading doses up to 20 g/day are
used by athletes. We have chosen not to use a loading
dose to avoid extremely high plasma concentrations with
potential side effects.
In contrast to our experimental animals, our patient
population was treated with a chronic high-dose multi-
vitamin regimen. High-dose folic acid supplementation
could mask the Hcy-lowering effect of creatine in this
population. A clinically relevant tHcy-lowering treat-
ment should be able to decrease tHcy levels in vitamin-
replete patients. Theoretically, lowering methylation
demand could be synergistic with folic acid supplemen-
tation, which enhances the remethylation pathway. In
contrast to these theoretic expectations, a decreased
methylation demand by exogenous creatine supplemen-
tation did not lower tHcy concentrations, despite docu-
mented uptake and metabolization of creatine.
2426 Taes et al: Creatine supplementation and homocysteine in hemodialysis
Table 3. Biochemical variables in both treatment groups
Period 1 Period 2
Ref. range Placebo Creatine Placebo Creatine
Body weight kg 68 ± 17 69 ± 10 69 ± 11 68 ± 17
Red cell creatine mmol/L 0.30 ± 0.06 0.42 ± 0.11b 0.25 ± 0.06 0.39 ± 0.06b
Plasma creatinine lmol/L 49–103 751 ± 194 884 ± 292c 769 ± 230 840 ± 239
Plasma urea mmol/L 2.8–8.0 23.3 ± 6.7 25.0 ± 6.7 26.7 ± 5.0 25.0 ± 6.7
AST U/La 0–37 17 (15–21) 16 (14–23) 16 (14–22) 16 (15–19)
ALT U/L 13–45 15 (11–19) 15 (12–19) 13 (12–19) 14 (11–17)
Alkaline phosphatase U/La 56–119 81 (60–103) 92 (75–122) 92 (75–119) 92 (62–120)
GGT U/La 11–49 22 (18–26) 21 (14–38) 20 (14–44) 18 (17–27)
Creatine kinase U/La 10–195 67 (42–78) 71 (37–99) 60 (33–87) 67 (52–78)
CRP mg/La <5 5 (2–10) 3 (1–8) 3 (1–9) 6 (1–10)
a 1-acid glycoprotein g/L 0.5–1.3 1.00 ± 0.25 0.98 ± 0.28 1.01 ± 0.27 1.01 ± 0.26
Albumin g/L 34–48 40.1 ± 4.7 39.5 ± 5.6 39.9 ± 4.8 40.0 ± 4.0
Prealbumin g/L 0.2–0.4 0.26 ± 0.07 0.28 ± 0.10 0.29 ± 0.08 0.25 ± 0.06
PINIa <1.0 0.47 (0.13–1.0) 0.25 (0.07–0.76) 0.25 (0.09–0.91) 0.42 (0.14–1.3)
Total protein g/L 66–83 67 ± 3.9 66 ± 4.5 66 ± 4.4 66 ± 35
Folate nmol/L 4.5–20.3 69.9 ± 13.4 63.2 ± 15.6 66.1 ± 19.1 73.0 ± 14.9
Vitamin B12 pmol/L 145–639 579 ± 192 483 ± 199 581 ± 190 636 ± 157
Abbreviations are: PINI, prognostic inflammatory and nutritional index; AST, aspartate-aminotransferase; ALT, alanine-aminotransferase; GGT, c-glutamyl
transferase.
aNon-Gaussian distribution, data expressed as median (interquartile range).
bP < 0.0001.
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Fig. 4. Relationship between plasma homo-
cysteine (tHcy) and plasma creatine (A),
plasma folate (B), Kt/Vurea (C), and plasma
creatinine concentrations (D). (A) and (B)
represent values (homocysteine, creatine, fo-
late) after treatment; (C) and (D) repre-
sent baseline values (homocysteine, creati-
nine, Kt/Vurea).
In our patient population, creatine supplementation
did not alter plasma folate concentrations. High-dose
folic acid supplementation could have masked the fo-
late sparing action of creatine that we have observed in
our animal model. Lowering methyl group consumption
by creatine supplementation apparently no longer influ-
ences tHcy or folate concentrations in conditions of ex-
cess folate [12].
Species-related differences in metabolic pathways
could perhaps explain the difference in effect between
humans and rodents. In rats, about 75% of plasma tHcy
was found to be free, whereas in humans, about 65% to
75% of tHcy is bound to protein by a disulfide bond [21,
22]. In dialysis patients, protein binding of Hcy was even
found to be higher in comparison to nondialyzed chronic
uremic patients [23]. These differences in protein binding
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could be reflected in differences found in renal extraction
of Hcy in humans and rats. In rats, significant clearance
of Hcy by the kidneys was observed [22], whereas in hu-
mans, no arteriovenous difference in Hcy concentrations
was observed [24]. Differences in renal handling and in
general Hcy metabolism could account for the absence
of effect of creatine supplementation in our study. Aside
from dissimilarities in Hcy-metabolism, creatine could
be metabolized differently in rats than in humans. Com-
partmentalization and possibly regulation of the different
enzymes necessary for creatine biosynthesis differs sub-
stantially between species [6, 25].
In uremia, a disturbed SAM/SAH ratio inhibits the
methyltransferase reactions. Creatine supplementation
has been described to reduce the guanidinoacetate-
methyltransferase reaction by lowering guanidinoac-
etate concentrations. The influence of creatine on other
methyltransferase reactions (e.g., DNA-, protein methyl-
transferases) is currently unknown. Because creatine sup-
plementation fails to lower tHcy concentrations in our
dialysis population, the effect on other methyltransferase
reactions will probably be limited in humans.
The safety of creatine supplementation and the ab-
sence of adverse effects on renal function were previously
assessed by our group in an animal model of chronic renal
failure [26]. No adverse effects on glomerular filtration or
renal protein handling were observed. Although adverse
effects of creatine have been suggested, none of the con-
trolled studies in humans on the effects of creatine sup-
plementation have revealed any [27]. In our hemodialysis
population we did not observe any major adverse effect
of creatine administration. Plasma creatinine concentra-
tions were slightly elevated due to increased creatine load
in the creatine groups compared to the placebo groups.
No effect on body weight or liver enzymes was noted.
Protein malnutrition is common in patients on main-
tenance dialysis. Malnutrition and hypoalbuminemia are
risk factors for increased morbidity and mortality in pa-
tients with ESRD [28, 29]. Nutritional status influences
plasma tHcy concentrations by the strong protein bind-
ing of Hcy to albumin, and by the increased Hcy forma-
tion upon methionine uptake from the diet. The PINI
is a formula to evaluate nutritional status and progno-
sis in critically ill patients [14, 15]. The PINI score has
been measured in several settings, and has been found
to be a reliable indicator of both nutritional status and
prognosis. The PINI score was determined in this study
in order to take into account the effect of protein mal-
nutrition on tHcy concentrations. In our population we
evaluated the relationship between nutritional status by
means of the PINI score and tHcy concentrations, as
tHcy depend greatly on protein intake [30, 31]. Dur-
ing the study no changes in nutritional status were ob-
served in either creatine- or placebo-treated group. We
observed no correlation between PINI scores, albumin or
prealbumin concentrations, and tHcy concentrations. In
conditions of excess folate, nutritional status could be of
less importance in determining plasma tHcy concentra-
tions.
Creatine supplementation has been shown to exert er-
gogenic effects in several populations. In dialysis patients,
creatine supplementation was shown to decrease muscle
cramps during dialysis [32]. In other conditions associated
with low muscular mass and performance [33], creatine
was shown to increase muscular performance and quality
of life. Further research is necessary to evaluate the po-
tential use and mechanisms of creatine as an ergogenic
substance in dialysis patients.
CONCLUSION
The present study demonstrated that inhibition of
endogenous methylation demand with dietary creatine
supplementation does not further decrease tHcy concen-
trations in chronic dialysis patients treated with high-dose
folic acid, vitamin B6, and B12 supplementation.
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